Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey

Yildiz, Birol; Hacioglu, Muhammet Bekir; Kostek, Osman; Karabulut, Senem; SEZGİN GÖKSU, SEMA; Alandag, Celal; Akagunduz, Baran; Bilgetekin, Irem; Caner, Burcu; ŞAHİN, AHMET BİLGEHAN; Kose, Fatih; Kaplan, Muhammet Ali; Gulmez, Ahmet; DOĞAN, ENDER; Guven, Deniz Can; Gurbuz, Mustafa; Ergun, Yakup; KARAAĞAÇ, MUSTAFA; Demiray, Atike Gokcen; Turker, Sema; Sakalar, Teoman; Ozkul, Ozlem; Telli, Tugba Akin; Sahin, Suleyman; KILIÇKAP, SAADETTİN; Bilici, Ahmet; ERDOĞAN, BÜLENT; ÇİÇİN, İRFAN; Tastekin, Didem

Tarih

2020

Yazar

Yildiz, Birol

Hacioglu, Muhammet Bekir

Kostek, Osman

Karabulut, Senem

SEZGİN GÖKSU, SEMA

Alandag, Celal

Akagunduz, Baran

Bilgetekin, Irem

Caner, Burcu

ŞAHİN, AHMET BİLGEHAN

Kose, Fatih

Kaplan, Muhammet Ali

Gulmez, Ahmet

DOĞAN, ENDER

Guven, Deniz Can

Gurbuz, Mustafa

Ergun, Yakup

KARAAĞAÇ, MUSTAFA

Demiray, Atike Gokcen

Turker, Sema

Sakalar, Teoman

Ozkul, Ozlem

Telli, Tugba Akin

Sahin, Suleyman

KILIÇKAP, SAADETTİN

Bilici, Ahmet

ERDOĞAN, BÜLENT

ÇİÇİN, İRFAN

Tastekin, Didem

Üst veri

Tüm öğe kaydını göster

Özet

Purpose: After failure of the first-line sorafenib treatment in advanced or metastatic stage hepatocellular carcinoma (HCC), regorafenib is one of the newly-approved targeted agents. We aimed to evaluate the efficacy of regorafenib in patients with advanced HCC treated in the secondor third-line setting.

Bağlantı

http://hdl.handle.net/20.500.12627/4404

Koleksiyonlar

Makale [92796]